Zenith Capital Corp. (ZHCLF)
USD 0.0
(-99.9%)
USD 0.0
(-99.9%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 27.56 Thousand USD | 52.91% |
| 2022 | 18.03 Thousand USD | 236.13% |
| 2021 | 5364.00 USD | -2.9% |
| 2020 | 5524.00 USD | -19.71% |
| 2019 | 6880.00 USD | -10.54% |
| 2018 | 7691.00 USD | 353.21% |
| 2017 | 1697.00 USD | -45.12% |
| 2016 | 3092.00 USD | -72.35% |
| 2015 | 11.18 Thousand USD | 53.35% |
| 2014 | 7293.00 USD | 1.89% |
| 2013 | 7158.00 USD | -62.11% |
| 2012 | 18.89 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 29.97 Thousand USD | 8.71% |
| 2023 Q1 | 7701.00 USD | 15.32% |
| 2023 Q2 | 11.04 Thousand USD | 43.36% |
| 2023 Q4 | 27.56 Thousand USD | 4.27% |
| 2023 Q3 | 26.43 Thousand USD | 139.48% |
| 2022 Q3 | 5867.00 USD | 14.88% |
| 2022 Q4 | 6678.00 USD | 13.82% |
| 2022 FY | 6678.00 USD | 24.5% |
| 2022 Q1 | 6009.00 USD | 12.02% |
| 2022 Q2 | 5107.00 USD | -15.01% |
| 2021 Q3 | 4584.00 USD | -30.93% |
| 2021 Q2 | 6637.00 USD | 23.92% |
| 2021 FY | 5364.00 USD | -2.9% |
| 2021 Q4 | 5364.00 USD | 17.02% |
| 2021 Q1 | 5356.00 USD | -3.04% |
| 2020 Q4 | 5524.00 USD | 32.72% |
| 2020 Q1 | 5145.00 USD | -25.22% |
| 2020 FY | 5524.00 USD | -19.71% |
| 2020 Q2 | 3447.00 USD | -33.0% |
| 2020 Q3 | 4162.00 USD | 20.74% |
| 2019 FY | 6880.00 USD | -10.54% |
| 2019 Q4 | 6880.00 USD | -48.02% |
| 2019 Q3 | 13.23 Thousand USD | 31.26% |
| 2019 Q2 | 10.08 Thousand USD | -6.64% |
| 2019 Q1 | 10.8 Thousand USD | 40.44% |
| 2018 Q2 | 3072.00 USD | 11.1% |
| 2018 Q3 | 3600.00 USD | 17.19% |
| 2018 Q4 | 7691.00 USD | 113.64% |
| 2018 FY | 7691.00 USD | 353.21% |
| 2018 Q1 | 2765.00 USD | 62.93% |
| 2017 Q4 | 1697.00 USD | 38.98% |
| 2017 FY | 1697.00 USD | -45.12% |
| 2017 Q3 | 1221.00 USD | -6.0% |
| 2017 Q2 | 1299.00 USD | -52.71% |
| 2017 Q1 | 2747.00 USD | -11.16% |
| 2016 Q4 | 3092.00 USD | 36.63% |
| 2016 FY | 3092.00 USD | -72.35% |
| 2016 Q1 | 2532.00 USD | -77.36% |
| 2016 Q2 | 2280.00 USD | -9.95% |
| 2016 Q3 | 2263.00 USD | -0.75% |
| 2015 Q2 | 7575.00 USD | 27.01% |
| 2015 Q1 | 5964.00 USD | -18.22% |
| 2015 Q4 | 11.18 Thousand USD | 18.74% |
| 2015 FY | 11.18 Thousand USD | 53.35% |
| 2015 Q3 | 9419.00 USD | 24.34% |
| 2014 Q3 | 5629.00 USD | -9.02% |
| 2014 Q2 | 6187.00 USD | -21.31% |
| 2014 Q1 | 7862.00 USD | 9.84% |
| 2014 Q4 | 7293.00 USD | 29.56% |
| 2014 FY | 7293.00 USD | 1.89% |
| 2013 Q4 | 7158.00 USD | 133.85% |
| 2013 FY | 7158.00 USD | -62.11% |
| 2013 Q3 | 3061.00 USD | 34.2% |
| 2013 Q2 | 2281.00 USD | -17.44% |
| 2013 Q1 | 2763.00 USD | -85.38% |
| 2012 FY | 18.89 Thousand USD | 0.0% |
| 2012 Q4 | 18.89 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -0.496% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 99.709% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.962% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 96.591% |
| Rebus Holdings, Inc. | 5.24 Million USD | 99.474% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.953% |
| Qrons Inc. | 1.48 Million USD | 98.148% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 97.752% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.963% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | 38.319% |
| Skye Bioscience, Inc. | 14.07 Million USD | 99.804% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.948% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 99.712% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 93.46% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.945% |
| Intellipharmaceutics International Inc. | 12 Million USD | 99.77% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 99.284% |
| Mesoblast Limited | 188.44 Million USD | 99.985% |
| Marizyme, Inc. | 26.67 Million USD | 99.897% |
| Genus plc | 485 Million USD | 99.994% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 99.528% |
| Pharming Group N.V. | 244.07 Million USD | 99.989% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 98.628% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 98.904% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 99.275% |
| ContraFect Corporation | 32.53 Million USD | 99.915% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 98.609% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 99.28% |
| IMV Inc. | 37.93 Million USD | 99.927% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 99.766% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1604.241% |
| ONE Bio Corp. | 27.49 Million USD | 99.9% |
| Accustem Sciences Inc. | 1.07 Million USD | 97.446% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.964% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 98.697% |
| Q BioMed Inc. | 8.13 Million USD | 99.661% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.967% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 99.464% |
| Biomind Labs Inc. | 1.49 Million USD | 98.16% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.977% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 99.695% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 99.85% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 98.077% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | 80.598% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | 86.292% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 99.52% |
| GB Sciences, Inc. | 5.41 Million USD | 99.491% |
| Alpha Cognition Inc. | 7.16 Million USD | 99.615% |
| HST Global, Inc. | 593.59 Thousand USD | 95.356% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 97.811% |
| Halberd Corporation | 728.71 Thousand USD | 96.217% |
| Enzolytics Inc. | 365.26 Million USD | 99.992% |
| Agentix Corp. | 2.51 Million USD | 98.902% |
| Resverlogix Corp. | 67.39 Million USD | 99.959% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 96.713% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.994% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 98.392% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 99.889% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 99.768% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 99.248% |
| AVAX Technologies, Inc. | 3.99 Million USD | 99.31% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.998% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 88.448% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 99.262% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 95.951% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 98.983% |
| Kadimastem Ltd | 3.5 Million USD | 99.213% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | 58.809% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.945% |
| BioStem Technologies, Inc. | 15.9 Million USD | 99.827% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 94.067% |
| LadRx Corporation | 2.2 Million USD | 98.747% |
| Cell Source, Inc. | 15.8 Million USD | 99.826% |
| Regen BioPharma, Inc. | 5.45 Million USD | 99.495% |
| Regen BioPharma, Inc. | 5.45 Million USD | 99.495% |
| NovAccess Global Inc. | 7.86 Million USD | 99.649% |
| Affymax, Inc. | 8.87 Million USD | 99.689% |
| Itoco Inc. | 1.65 Million USD | 98.332% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 98.656% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 99.544% |
| Mobile Lads Corp. | 1.31 Million USD | 97.901% |
| CytoDyn Inc. | 127.89 Million USD | 99.978% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | 34.044% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 98.24% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 99.75% |
| SYBLEU INC | 681.41 Thousand USD | 95.954% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 99.548% |
| International Stem Cell Corporation | 5.27 Million USD | 99.478% |
| Bioxytran, Inc. | 3.24 Million USD | 99.152% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 95.595% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 99.403% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 99.933% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 99.876% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 98.639% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 99.497% |
| Neutra Corp. | 973.52 Thousand USD | 97.168% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 99.905% |
| PureTech Health plc | 125.58 Million USD | 99.978% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 99.266% |
| IXICO plc | 1.9 Million USD | 98.549% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 99.866% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.973% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Cellectis S.A. | 249.36 Million USD | 99.989% |